Monte Rosa Therapeutics (GLUE) Projected to Post Quarterly Earnings on Thursday

Monte Rosa Therapeutics (NASDAQ:GLUE) is anticipated to issue its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Monte Rosa Therapeutics to post earnings of ($0.34) per share and revenue of $7.3710 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 13, 2025 at 7:00 AM ET.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its earnings results on Thursday, August 7th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.16. Monte Rosa Therapeutics had a net margin of 13.58% and a return on equity of 9.95%. The business had revenue of $23.19 million during the quarter, compared to the consensus estimate of $7.23 million. On average, analysts expect Monte Rosa Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Monte Rosa Therapeutics Trading Down 0.3%

GLUE opened at $12.03 on Tuesday. Monte Rosa Therapeutics has a 1-year low of $3.50 and a 1-year high of $13.22. The company has a market cap of $742.97 million, a P/E ratio of 33.46 and a beta of 1.61. The company has a fifty day moving average price of $7.82 and a two-hundred day moving average price of $5.82.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of Monte Rosa Therapeutics in a research note on Friday. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $15.33.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Man Group plc bought a new position in Monte Rosa Therapeutics in the 2nd quarter worth $164,000. Lazard Asset Management LLC increased its stake in shares of Monte Rosa Therapeutics by 42.9% in the 2nd quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after acquiring an additional 3,262 shares in the last quarter. Bridgeway Capital Management LLC bought a new position in shares of Monte Rosa Therapeutics in the 2nd quarter worth about $1,224,000. Bank of America Corp DE increased its stake in shares of Monte Rosa Therapeutics by 941.1% in the 2nd quarter. Bank of America Corp DE now owns 271,164 shares of the company’s stock worth $1,223,000 after acquiring an additional 245,119 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in shares of Monte Rosa Therapeutics by 459.4% in the 2nd quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock worth $5,791,000 after acquiring an additional 1,054,406 shares in the last quarter. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.